These Analysts Cut Their Forecasts On BridgeBio Oncology After Q3 Results
Piper Sandler Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $15
Wedbush Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $9
BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
BridgeBio Oncology Q3 EPS $(0.43) Beats $(0.69) Estimate
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16
BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22
Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15
Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers
BBOT to Participate in Upcoming Investor Healthcare Conferences
JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.